Traws Pharma targets 3Q 2026 MHRA resubmission to advance TXM Phase 2a influenza challenge study

Traws Pharma, Inc.

Traws Pharma, Inc.

TRAW

0.00
  • Traws Pharma outlined plans to resubmit an updated toxicology package to the UK MHRA in 3Q 2026 for tivoxavir marboxil.
  • The filing targets clearance to start a Phase 2a human seasonal influenza challenge study in healthy volunteers; no clinical results have been presented.
  • Management expects the updated package to address MHRA requirements, aiming to keep the prophylaxis program moving toward proof-of-concept readouts.
  • MHRA feedback prompted additional preclinical safety work; a formal agency response is expected within 30 days of resubmission.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-076058), on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.